



an Open Access Journal by MDPI

## Multi-Drug Resistant Gram-Negative Infections: Molecular Epidemiology, Microbiological Diagnosis and Antimicrobial Treatment

Guest Editors:

**Dr. Simone Ambretti**

IRCCS Azienda Ospedaliera,  
Universitaria di Bologna,  
Policlinico di S.Orsola, Bologna,  
Italy

**Dr. Paolo Gaibani**

IRCCS Azienda Ospedaliera,  
Universitaria di Bologna,  
Policlinico di S.Orsola, Bologna,  
Italy

**Dr. Tommaso Gianì**

Department of Experimental and  
Clinical Medicine, University of  
Florence, Florence, Italy

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Infections caused by gram-negative pathogens have become increasingly prevalent in recent years, representing a serious global threat to public health. The majority of the burden is related to healthcare-acquired infections caused by gram-negative multi-drug resistant organisms, including extended-spectrum  $\beta$ -lactamase (ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant *Acinetobacter baumannii* (CRAB), and MDR *Pseudomonas aeruginosa*.

We invite authors to send in their manuscripts in the following areas of interest:

- novel in vitro diagnostic tools for MDR gram-negative detection and antimicrobial susceptibility testing;
- molecular epidemiology of gram-negative pathogens and resistance mechanisms;
- evaluation of antimicrobial treatment regimens for MDR gram-negatives infections;
- new drugs against MDR gram-negatives: clinical use, in vitro susceptibility testing and emerging resistance.



[mdpi.com/si/87048](https://mdpi.com/si/87048)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi